These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 20967817)
1. Bioorthogonal small-molecule ligands for PARP1 imaging in living cells. Reiner T; Earley S; Turetsky A; Weissleder R Chembiochem; 2010 Nov; 11(17):2374-7. PubMed ID: 20967817 [No Abstract] [Full Text] [Related]
2. [PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective]. Wiśnik E; Ryksa M; Koter-Michalak M Postepy Hig Med Dosw (Online); 2016 Apr; 70():280-94. PubMed ID: 27117104 [TBL] [Abstract][Full Text] [Related]
3. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Brenner JC; Ateeq B; Li Y; Yocum AK; Cao Q; Asangani IA; Patel S; Wang X; Liang H; Yu J; Palanisamy N; Siddiqui J; Yan W; Cao X; Mehra R; Sabolch A; Basrur V; Lonigro RJ; Yang J; Tomlins SA; Maher CA; Elenitoba-Johnson KS; Hussain M; Navone NM; Pienta KJ; Varambally S; Feng FY; Chinnaiyan AM Cancer Cell; 2011 May; 19(5):664-78. PubMed ID: 21575865 [TBL] [Abstract][Full Text] [Related]
4. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications. Park SH; Jang KY; Kim MJ; Yoon S; Jo Y; Kwon SM; Kim KM; Kwon KS; Kim CY; Woo HG Oncotarget; 2015 Dec; 6(42):44819-31. PubMed ID: 26540566 [TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
7. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy. Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827 [TBL] [Abstract][Full Text] [Related]
8. Identification of poly(ADP-ribose)polymerase 1 and 2 (PARP1/2) as targets of andrographolide using an integrated chemical biology approach. Li W; Pan B; Shi Y; Wang M; Han T; Wang Q; Duan G; Fu H Chem Commun (Camb); 2021 Jun; 57(51):6308-6311. PubMed ID: 34075974 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Reiner T; Keliher EJ; Earley S; Marinelli B; Weissleder R Angew Chem Int Ed Engl; 2011 Feb; 50(8):1922-5. PubMed ID: 21328671 [No Abstract] [Full Text] [Related]
11. PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells. Schacke M; Kumar J; Colwell N; Hermanson K; Folle GA; Nechaev S; Dhasarathy A; Lafon-Hughes L Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691122 [TBL] [Abstract][Full Text] [Related]
12. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384 [TBL] [Abstract][Full Text] [Related]
13. Expression of human poly (ADP-ribose) polymerase 1 in Saccharomyces cerevisiae: Effect on survival, homologous recombination and identification of genes involved in intracellular localization. La Ferla M; Mercatanti A; Rocchi G; Lodovichi S; Cervelli T; Pignata L; Caligo MA; Galli A Mutat Res; 2015 Apr; 774():14-24. PubMed ID: 25779917 [TBL] [Abstract][Full Text] [Related]
14. A rapid fluorescent method for the real-time measurement of poly(ADP-ribose) polymerase 1 activity. Kurgina TA; Anarbaev RO; Sukhanova MV; Lavrik OI Anal Biochem; 2018 Mar; 545():91-97. PubMed ID: 29326071 [TBL] [Abstract][Full Text] [Related]
15. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy. Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916 [TBL] [Abstract][Full Text] [Related]
16. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319 [TBL] [Abstract][Full Text] [Related]
18. Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity. Reilly SW; Puentes LN; Wilson K; Hsieh CJ; Weng CC; Makvandi M; Mach RH J Med Chem; 2018 Jun; 61(12):5367-5379. PubMed ID: 29856625 [TBL] [Abstract][Full Text] [Related]
19. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Reiner T; Lacy J; Keliher EJ; Yang KS; Ullal A; Kohler RH; Vinegoni C; Weissleder R Neoplasia; 2012 Mar; 14(3):169-77. PubMed ID: 22496617 [TBL] [Abstract][Full Text] [Related]
20. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways. Ghosh R; Roy S; Kamyab J; Danzter F; Franco S DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]